Señales en vivo de GKOS | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 abr 2024 @ 16:00):

Stats
Volumen de hoy	424 987
Volumen promedio	502 818
Capitalización de mercado	4.82B
EPS	$0 ( 2024-02-21 )
Próxima fecha de ganancias	( $-0.580 ) 2024-05-30
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-34.53
ATR14	$0.0680 (0.07%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Hoffmeister David F	Buy	10 000	Common Stock
2024-04-10	Hoffmeister David F	Sell	10 000	Stock Option (Right to Buy)
2024-04-08	Gilliam Joseph E	Buy	59 801	Common Stock
2024-04-08	Gilliam Joseph E	Sell	10 456	Common Stock
2024-04-08	Gilliam Joseph E	Sell	41 068	Common Stock

INSIDER POWER
0.86
Last 100 transactions
Buy: 501 923 \| Sell: 495 631

Volumen Correlación

Largo: -0.63 (weak negative)

Corto: -0.61 (weak negative)

Signal:(25.348) Neutral

Glaukos Corp Correlación

10 Correlaciones Más Positivas
HDIV	0.826
LXFR	0.808
NXN	0.804
BFS-PD	0.803

10 Correlaciones Más Negativas
FORG	-0.813

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Glaukos Corp Correlación - Moneda/Commodity

0.61
( weak )

0.72
( moderate )

0.60
( weak )

0.43
( neutral )

-0.32
( neutral )

Glaukos Corp Finanzas

Annual	2023
Ingresos:	$314.71M
Beneficio Bruto:	$239.14M (75.99 %)
EPS:	$-2.78

FY	2023
Ingresos:	$314.71M
Beneficio Bruto:	$239.14M (75.99 %)
EPS:	$-2.78

FY	2022
Ingresos:	$282.86M
Beneficio Bruto:	$213.88M (75.61 %)
EPS:	$-2.09

FY	2021
Ingresos:	$294.01M
Beneficio Bruto:	$227.38M (77.34 %)
EPS:	$-1.070

Financial Reports:

No articles found.

Glaukos Corp

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Actualizaciones en tiempo real para Glaukos Corp [GKOS]

Upcoming Earnings Alert